AIFA successfully completed inspection of Labochim
Infa Group is very pleased to announce that the Italian Health Authorities (AIFA) inspection of Labochim, has been successfully completed.
AIFA inspected Labochim, one of Infa Group’s active pharmaceutical ingredient (API) manufacturing facilities, from May 25 to 29, 2015 and found the site to be compliant to current GMP guidelines.
The GMP inspection was at the request of Infa Group to obtain an official authorization of the recently built HP API facility.
The new facility is fully operational according to Pharmaceutical cGMP, with capacity ranging from a hundred grams to tens of kilograms of both advanced intermediates and APIs.
This investment will enable INFA to strengthen its product portfolio and services for the Generic as well as the CDMO segments.
The project was realized with highest quality standards offering unique flexibility to Infa customers and thus differentiating Infa Group’s new Multipurpose GMP HPAPI from all others. The plant will be wholly dedicated to therapeutic areas outside of Oncology.
Daniele Cardoso, President of Infa Group commented, “We congratulate our people for their contribution in preparing and conducting this audit. We continue to work with the same commitment and dedication to our customers in order to ever improve the level of excellence” Luca Mantovani, CEO of Infa Group added, “This investment will open up unique opportunities for our Company in order to serve clients requiring high-containment capabilities for product and projects in many therapeutic segments where we are very strong outside the oncological area. ”